Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
from PLoS One
It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. More than two TACE procedures within six months might be associated with the refractoriness to TACE in patients with recurrent HCC after curative resection.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063